Search

Your search keyword '"Pigrau, Carles"' showing total 153 results
Start Over Author "Pigrau, Carles"
153 results on '"Pigrau, Carles"'

1. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial

Author

Rodríguez-Pardo, Dolors, del Toro, María Dolores, Guío-Carrión, Laura, Escudero-Sánchez, Rosa, Fernández-Sampedro, Marta, García-Viejo, Miguel Ángel, Velasco-Arribas, María, Soldevila-Boixader, Laura, Femenias, Magdalena, Iribarren, José Antonio, Pulido-Garcia, María del Carmen, Navarro, María Dolores, Lung, Mayli, Corona, Pablo S., Almirante, Benito, and Pigrau, Carles

Published
2021
Full Text
View/download PDF

10. Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study

Author

Willekens, Rein, primary, Puig-Asensio, Mireia, additional, Suanzes, Paula, additional, Fernández-Hidalgo, Nuria, additional, Larrosa, Maria N, additional, González-López, Juan J, additional, Rodríguez-Pardo, Dolors, additional, Pigrau, Carles, additional, and Almirante, Benito, additional

Published
2022
Full Text
View/download PDF

12. Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study

Author

Willekens, Rein, primary, Puig-Asensio, Mireia, additional, Suanzes, Paula, additional, Fernández-Hidalgo, Nuria, additional, Larrosa, Maria N., additional, González-López, Juan J., additional, Rodríguez-Pardo, Dolors, additional, Pigrau, Carles, additional, and Almirante, Benito, additional

Published
2021
Full Text
View/download PDF

15. Periprosthetic Joint Infection Prophylaxis in the Elderly after Hip Hemiarthroplasty in Proximal Femur Fractures : Insights and Challenges

Author

Rodriguez-Pardo, Dolors, Escolà-Vergé, Laura, Sellarès-Nadal, Júlia, Corona, Pablo S., Almirante Gragera, Benito, Pigrau, Carles, Rodriguez-Pardo, Dolors, Escolà-Vergé, Laura, Sellarès-Nadal, Júlia, Corona, Pablo S., Almirante Gragera, Benito, and Pigrau, Carles

Abstract

We review antibiotic and other prophylactic measures to prevent periprosthetic joint infection (PJI) after hip hemiarthroplasty (HHA) surgery in proximal femoral fractures (PFFs). In the absence of specific guidelines, those applied to these individuals are general prophylaxis guidelines. Cefazolin is the most widely used agent and is replaced by clindamycin or a glycopeptide in beta-lactam allergies. A personalized antibiotic scheme may be considered when colonization by a multidrug-resistant microorganism (MDRO) is suspected. Particularly in methicillin-resistant Staphylococcus aureus (MRSA) colonization or a high prevalence of MRSA-caused PJIs a glycopeptide with cefazolin is recommended. Strategies such as cutaneous decolonization of MDROs, mainly MRSA, or preoperative asymptomatic bacteriuria treatment have also been addressed with debatable results. Some areas of research are early detection protocols in MDRO colonizations by polymerase-chain-reaction (PCR), the use of alternative antimicrobial prophylaxis, and antibiotic-impregnated bone cement in HHA. Given that published evidence addressing PJI prophylactic strategies in PFFs requiring HHA is scarce, PJIs can be reduced by combining different prevention strategies after identifying individuals who will benefit from personalized prophylaxis

Published
2021

16. Candida Periprosthetic Joint Infection : Is It Curable?

Author

Escolà-Vergé, Laura, Rodriguez-Pardo, Dolors, Corona, Pablo S., Pigrau, Carles, Universitat Autònoma de Barcelona, Escolà-Vergé, Laura, Rodriguez-Pardo, Dolors, Corona, Pablo S., Pigrau, Carles, and Universitat Autònoma de Barcelona

Abstract

Candida periprosthetic joint infection (CPJI) is a rare and very difficult to treat infection, and high-quality evidence regarding the best management is scarce. Candida spp. adhere to medical devices and grow forming biofilms, which contribute to the persistence and relapse of this infection. Typically, CPJI presents as a chronic infection in a patient with multiple previous surgeries and long courses of antibiotic therapy. In a retrospective series of cases, the surgical approach with higher rates of success consists of a two-stage exchange surgery, but the best antifungal treatment and duration of antifungal treatment are still unclear, and the efficacy of using an antifungal agent-loaded cement spacer is still controversial. Until more evidence is available, focusing on prevention and identifying patients at risk of CPJI seems more than reasonable

Published
2021

17. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial

Author

Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CT406. Estudio de enfermedades infecciosas en la práctica clínica, ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Rodríguez-Pardo, Dolors, Toro López, María Dolores del, Guío-Carrión, Laura, Escudero-Sánchez, Rosa, Fernández-Sampedro, Marta, García-Viejo, Miguel Ángel, Pigrau, Carles, Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CT406. Estudio de enfermedades infecciosas en la práctica clínica, ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Rodríguez-Pardo, Dolors, Toro López, María Dolores del, Guío-Carrión, Laura, Escudero-Sánchez, Rosa, Fernández-Sampedro, Marta, García-Viejo, Miguel Ángel, and Pigrau, Carles

Abstract

Purpose To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Methods Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. Primary outcome: early-PJI after HHA. Results Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33–3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15–7.10]). Conclusions Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47

Published
2021

21. Role of asymptomatic bacteriuria on early periprosthetic joint infection after Hip Hemiarthroplasty. BARIFER randomized clinical trial.

Author

Rodriguez-Pardo, Dolors, primary, Toro, María Dolores Del, additional, Carrión, Laura Guio, additional, Escudero, Rosa, additional, Fernández-Sampedro, Marta, additional, Viejo, Miguel Ángel García, additional, Arribas, María Velasco, additional, Soldevila-Boixader, Laura, additional, Femenias, Magdalena, additional, Iribarren, José Antonio, additional, Pulido-Garcia, María del Carmen, additional, Navarro, Mª Dolores, additional, Lung, Mayli, additional, Corona, Pablo S, additional, Almirante, Benito, additional, and Pigrau, Carles, additional

Published
2021
Full Text
View/download PDF

22. Daptomycin plus Fosfomycin versus Daptomycin Alone for Methicillin-Resistant Staphylococcus 2 aureus Bacteremia and Endocarditis. A Randomized Clinical Trial

Author

Pujol, Miquel, Miró Meda, José M., Shaw, Evelyn, Aguado, José María, San Juan, Rafael, Puig Asensio, Mireia, Pigrau, Carles, Calbo, Esther, Montejo, Miguel, Rodriguez Álvarez, Regino, Garcia Pais, María Jose, Pintado, Vicente, Escudero Sánchez, Rosa, Lopez Contreras, Joaquín, Morata, Laura, Montero, Milagros, Andrés, Marta, Pasquau, Juan, Arenas, María del Mar, Padilla, Belén, Murillas, Javier, Jover Sáenz, Alfredo, López Cortes, Luis Eduardo, García Pardo, Graciano, Gasch, Oriol, Videla, Sebastian, Hereu, Pilar, Tebé, Cristian, Pallarès, Natàlia, Sanllorente, Mireia, Domínguez Luzón, Ma. Ángeles (María Ángeles), Càmara, Jordi, Ferrer, Anna, Padullés Zamora, Ariadna, Cuervo Requena, Guillermo, Carratalà, Jordi, and MRSA Bacteremia (BACSARM) Trial Investigators

Subjects
Clinical trials, Endocarditis, Bacteria, Antibiotics, lipids (amino acids, peptides, and proteins), Antibiòtics, biochemical phenomena, metabolism, and nutrition, Malalties infeccioses, Communicable diseases, bacterial infections and mycoses, Bacteris, Assaigs clínics
Abstract

Background We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Methods A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Results Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). Conclusions Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.

Published
2020

24. Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

Author

Gómez-Junyent, Joan, primary, Lora-Tamayo, Jaime, additional, Baraia-Etxaburu, Josu, additional, Sánchez-Somolinos, Mar, additional, Iribarren, Jose Antonio, additional, Rodriguez-Pardo, Dolors, additional, Praena-Segovia, Julia, additional, Sorlí, Luisa, additional, Bahamonde, Alberto, additional, Riera, Melchor, additional, Rico, Alicia, additional, del Toro, Mª Dolores, additional, Morata, Laura, additional, Cobo, Javier, additional, Falgueras, Luis, additional, Benito, Natividad, additional, Muñez, Elena, additional, Jover-Sáenz, Alfredo, additional, Pigrau, Carles, additional, Ariza, Javier, additional, and Murillo, Oscar, additional

Published
2021
Full Text
View/download PDF

27. The Different Microbial Etiology of Prosthetic Joint Infections According to Route of Acquisition and Time After Prosthesis Implantation, Including the Role of Multidrug-Resistant Organisms

Author

Benito, Natividad, Mur, Isabel, Ribera, Alba, Soriano, Alex, Rodriguez-Pardo, Dolors, Sorli, Luisa, Cobo, Javier, Fernandez-Sampedro, Marta, Dolores del Toro, Maria, Guio, Laura, Praena, Julia, Bahamonde, Alberto, Riera, Melchor, Esteban, Jaime, Mirena Baraia-Etxaburu, Josu, Martinez-Alvarez, Jesus, Jover-Saenz, Alfredo, Duenas, Carlos, Ramos, Antonio, Sobrino, Beatriz, Euba, Gorane, Morata, Laura, Pigrau, Carles, Horcajada, Juan P., Coll, Pere, Crusi, Xavier, Ariza, Javier, Garcia-Gonzalez, Merce, Perez-Villar, Ferran, Prats-Gispert, Laura, Ramirez-Hidalgo, Maria, De-la-Pena-Trigueros, Mireia, Lopez-Azkarreta, Inigo, Lopez-Martinez, Miriam, Lora-Tamayo, Jaime, Murillo, Oscar, Pedrero, Salvador, Amador, Juan, Garcia-Paino, Luis, Parrondo, Susana, Raya, Carmen, Moreno, Alfonso, Aranzazu Blanco-Martinez-de-Morentin, Maria, Genoveva Zapico-Aldea, Laura Rodriguez-Fernandez, Lozano, Luis, Munoz-Mahamud, Ernesto, Merino-Perez, Josu, Alier, Albert, Prim, Nuria, Puig, Luis, Aunon, Alvaro, Blanco, Antonio, Garcia-Canete, Joaquin, Parron-Cambero, Raul, Carmen Farinas, M., Manuel-Bloque, Ricardo, Salas-Venero, Carlos, Campo-Loarte, Jesus, Munez-Rubio, Elena, Sanchez-Romero, Isabel, Escudero-Sanchez, Rosa, Ruiz-Carbajosa, Patricia, Gonzalez, Aranzazu, Carlos Gonzalez, Jose, Jordan, Marcos, Rivera, Alba, Marinescu, Carmen, Montaner, Francisco, Ramirez, Antonio, Corona, Pablo S., Lung, Maily, Puig-Asensio, Mireia, Angel Muniain-Ezcurra, Miguel, Penas-Espinar, Cecilia, Isabel Suarez, Ana, Jose Gomez, Maria, Lopez-Pliego, Macarena, REIPI Spanish Network Res Infect D, SEIMC Spanish Soc Infect Dis Clini, Universidad de Cantabria, Institut Català de la Salut, [Benito N, Mur I] Unitat de Malalties Infeccioses, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Institut d'Investigació Biomèdica Sant Pau, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. [Ribera A] Departament de Malalties Infeccioses, Hospital Universitari Bellvitge, Barcelona, Spain. [Soriano A] Departament de Malalties Infeccioses, Hospital Clínic Universitari, Barcelona, Spain. [Rodríguez-Pardo D, Pigrau C] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Sorlí L] Departament de Malalties Infeccioses, Parc de Salut Mar, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Etiology, retrospective study, coagulase negative Staphylococcus, lcsh:Medicine, Prosthesis, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], medicine.disease_cause, 0302 clinical medicine, revision arthroplasty, equipos y suministros::prótesis e implantes::prótesis articulares [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], non-fermenting Gram-negative bacterium, Bacteroides, Medicine, Pròtesis, Microorganismes - Resistència als medicaments, 030212 general & internal medicine, Equipment and Supplies::Prostheses and Implants::Joint Prosthesis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Candida, disease transmission, periprosthetic joint infection, biology, cons, immunosuppressive treatment, methicillin resistant Staphylococcus aureus, postoperative infection, Multidrug-Resistant Organisms, Articulacions artificials, General Medicine, Antimicrobial, Infeccions, infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones estafilocócicas [ENFERMEDADES], aged, female, risk factor, Staphylococcus aureus, Etiologia, Classification Schemes For Prosthetic Joint Infections, Articulacions - Cirurgia - Complicacions, fenómenos microbiológicos::fenómenos fisiológicos bacterianos::farmacorresistencia bacteriana::farmacorresistencia bacteriana múltiple [FENÓMENOS Y PROCESOS], Charlson Comorbidity Index, Gram positive cocci, prospective study, musculoskeletal diseases, Bacilli, Microbiological Phenomena::Bacterial Physiological Phenomena::Drug Resistance, Bacterial::Drug Resistance, Multiple, Bacterial [PHENOMENA AND PROCESSES], Prosthetic joint, 030106 microbiology, microbial identification, bacterium culture, Virulence, Corynebacterium, Infections, Article, Mycobacterium, Microbiology, acute hematogenous infection, 03 medical and health sciences, Enterobacteriaceae, male, bacterium isolation, Other subheadings::Other subheadings::/adverse effects [Other subheadings], extended spectrum beta lactamase producing Enterobacteriaceae, Staphylococcus epidermidis, human, Propionibacterium acnes, bacteremia, Prosthetic Joint Infections, Antimicrobial Empirical Treatment, nonhuman, business.industry, bacterial virulence, lcsh:R, Infeccions per estafilococs, Streptococcus, biology.organism_classification, Classification schemes for prosthetic joint, major clinical study, Multiple drug resistance, osteoarthritis, multicenter study, arthroplasty, prosthesis implantation, Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Staphylococcal Infections [DISEASES], observational study, Microbial Etiology, business, Enterococcus
Abstract

The aim of our study was to characterize the etiology of prosthetic joint infections (PJIs)&mdash, including multidrug-resistant organisms (MDRO)&mdash, by category of infection. A multicenter study of 2544 patients with PJIs was performed. We analyzed the causative microorganisms according to the Tsukayama&rsquo, s scheme (early postoperative, late chronic, and acute hematogenous infections (EPI, LCI, AHI) and &ldquo, positive intraoperative cultures&rdquo, (PIC)). Non-hematogenous PJIs were also evaluated according to time since surgery: &lt, 1 month, 2&ndash, 3 months, 4&ndash, 12 months, &gt, 12 months. AHIs were mostly caused by Staphylococcus aureus (39.2%) and streptococci (30.2%). EPIs were characterized by a preponderance of virulent microorganisms (S. aureus, Gram-negative bacilli (GNB), enterococci), MDROs (24%) and polymicrobial infections (27.4%). Conversely, coagulase-negative staphylococci (CoNS) and Cutibacterium species were predominant in LCIs (54.5% and 6.1%, respectively) and PICs (57.1% and 15.1%). The percentage of MDROs isolated in EPIs was more than three times the percentage isolated in LCIs (7.8%) and more than twice the proportion found in AHI (10.9%). There was a significant decreasing linear trend over the four time intervals post-surgery for virulent microorganisms, MDROs, and polymicrobial infections, and a rising trend for CoNS, streptococci and Cutibacterium spp. The observed differences have important implications for the empirical antimicrobial treatment of PJIs.

Published
2019

30. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study

Author

Meije, Yolanda, primary, Pigrau, Carles, additional, Fernández-Hidalgo, Núria, additional, Clemente, Mercedes, additional, Ortega, Lucía, additional, Sanz, Xavier, additional, Loureiro-Amigo, Jose, additional, Sierra, Montserrat, additional, Ayestarán, Ana, additional, Morales-Cartagena, Alejandra, additional, Ribera, Alba, additional, Duarte, Alejandra, additional, Abelenda, Gabriela, additional, Rodríguez-Baño, Jesús, additional, and Martínez-Montauti, Joaquim, additional

Published
2019
Full Text
View/download PDF

31. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.

Author

Pujol, Miquel, Miró, José-María, Shaw, Evelyn, Aguado, Jose-María, San-Juan, Rafael, Puig-Asensio, Mireia, Pigrau, Carles, Calbo, Esther, Montejo, Miguel, Rodriguez-Álvarez, Regino, Garcia-Pais, María-Jose, Pintado, Vicente, Escudero-Sánchez, Rosa, Lopez-Contreras, Joaquín, Morata, Laura, Montero, Milagros, Andrés, Marta, Pasquau, Juan, Arenas, María-del-Mar, and Padilla, Belén

Subjects
ANTIBIOTICS, BACTEREMIA, HOSPITALS, RELATIVE medical risk, COMBINATION drug therapy, INTRAVENOUS therapy, CONFIDENCE intervals, METHICILLIN-resistant staphylococcus aureus, ENDOCARDITIS, RANDOMIZED controlled trials, COMPARATIVE studies, PRE-tests & post-tests, TREATMENT effectiveness, DOSE-effect relationship in pharmacology, DESCRIPTIVE statistics, DAPTOMYCIN, STATISTICAL sampling
Abstract

Background We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Methods A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Results Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval,.93–1.8]; P  = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P  = .003) and lower complicated bacteremia (16.2% vs 32.1%; P  = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P  = .018). Conclusions Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events. Clinical Trials Registration NCT01898338. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. A case series of confusional states and other neurotoxic effects caused by ertapenem.

Author

Danés, Immaculada, Pérez, Eulàlia, Pigrau, Carles, Gracia, Rosa M., Perelló, Manel, Sueiras, Maria, Aguilera, Cristina, and Agustí, Antònia

Subjects
KIDNEY failure, KIDNEY physiology, SYMPTOMS, PHARMACOKINETICS, NEUROTOXICOLOGY, ERTAPENEM
Abstract

Ten cases of ertapenem neurotoxicity, mainly confusional states, are described, some of them with fatal outcomes. The majority of patients (90%) had a creatinine clearance (CrCl) < 50 mL/min/1.73m2 at some point during treatment and hypoalbuminaemia was always present when ertapenem treatment was started. The pharmacokinetic and pharmacodynamic properties of this carbapenem could favour a different profile, and approved doses can be excessive in some patients with moderate renal failure (CrCl 31–59 mL/min/1.73 m2). It may be necessary to re‐evaluate renal function during treatment and adjust doses or reconsider the adequacy of treatment based on clinical judgement, especially if relevant changes in the CrCl occur (i.e. a reduction to ≤30 mL/min/1.73 m2) or unexplained behavioural disorders are detected. The onset of the symptoms of ertapenem neurotoxicity can be insidious and go unnoticed, and so a knowledge and early suspicion of confusional states are important to improve the patient prognosis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial

Author

Murillo, Oscar, Ribera, Alba, Cabo, Xavier, Fresco, Gema, Ruiz-Garbajosa, Patricia, Leal, Joan, Puig, Luis, Sorlí, Luisa, Morata, Laura, Bori, Guillem, Martínez-Pastor, Juan C., Rodríguez-Pardo, Dolors, Puig-Asensio, Mireia, Sordé-Masip, Roger, Prats-Gispert, Laura, Pérez-Villar, Ferran, García-Gónzalez, Mercé, Esteban, Jaime, Blanco, Antonio, García-Cañete, Joaquín, Puente, Andrés, Domecq, Gabriel, Álvarez, Rocío, Peñas-Espinar, Cecilia, Muniain-Ezcurra, Miguel Ángel, Suárez, Ana-Isabel, Coll, Pere, Jordán, Marcos, Mur, Isabel, Ibarguren, Maialen, de la Herrán, Gaspar, Sánchez-Romero, Isabel, Jiménez-Cristóbal, Javier, Múñez-Rubio, Elena, Muntaner, Francisco, Ramírez, Antonio, Fariñas, María Carmen, Campo, Cristina, Fakkas, Michel, López-Azkarreta, Íñigo, Ibarra, Sofía, Cisterna, Ramón, Granados, Ana, Lora-Tamayo, Jaime, Euba, Gorane, Cobo, Javier, Horcajada, Juan Pablo, Soriano, Alex, Sandoval, Enrique, Pigrau, Carles, Benito, Natividad, Falgueras, Luis, Palomino, Julián, del Toro, María Dolores, Jover-Sáenz, Alfredo, Iribarren, José Antonio, Sánchez-Somolinos, Mar, Ramos, Antonio, Fernández-Sampedro, Marta, Riera, Melchor, Baraia-Etxaburu, Josu Mirena, and Ariza, Javier

Published
2016
Full Text
View/download PDF

36. Candida periprosthetic joint infection: A rare and difficult-to-treat infection

Author

Escolà-Vergé, Laura, primary, Rodríguez-Pardo, Dolors, additional, Lora-Tamayo, Jaime, additional, Morata, Laura, additional, Murillo, Oscar, additional, Vilchez, Helem, additional, Sorli, Luisa, additional, Carrión, Laura Guío, additional, Barbero, José Mª, additional, Palomino-Nicás, Julián, additional, Bahamonde, Alberto, additional, Jover-Sáenz, Alfredo, additional, Benito, Natividad, additional, Escudero, Rosa, additional, Sampedro, Marta Fernandez, additional, Vidal, Rafael Pérez, additional, Gómez, Lucía, additional, Corona, Pablo S., additional, Almirante, Benito, additional, Ariza, Javier, additional, and Pigrau, Carles, additional

Published
2018
Full Text
View/download PDF

37. Non-intravenous, carbapenem-sparing antibiotics for the treatment of bacteremia due to ESBL or AMP-C β-lactamase: A propensity score study

Author

Meije, Yolanda, primary, Pigrau, Carles, additional, Fernandez-Hidalgo, Nuria, additional, Clemente, Mercedes, additional, Ortega, Lucia, additional, Sanz, Xavier, additional, Loureiro-Amigo, Jose, additional, Sierra, Montserrat, additional, Morales-Cartagena, Alejandra, additional, Ribera, Alba, additional, Ayestarán, Ana, additional, Rodríguez-Baño, Jesús, additional, and Martínez-Montauti, Joaquín, additional

Published
2018
Full Text
View/download PDF

39. Infections by OXA-48-like-producing Klebsiella pneumoniaenon-co-producing extended-spectrum beta-lactamase: Can they be successfully treated with cephalosporins?

Author

Escolà-Vergé, Laura, Larrosa, Nieves, Los-Arcos, Ibai, Viñado, Belen, González-López, Juan José, Pigrau, Carles, Almirante, Benito, and Len, Oscar

Abstract

•OXA-48-like carbapenemases have low hydrolytic activity against cephalosporins.•Ceftazidime is active against OXA-48-like producers lacking extended-spectrum β-lactamases (ESBL) in animal models.•Cephalosporins were effective to treat ESBL-negative OXA-48-producing K. pneumoniaeinfections.•However, further clinical studies should be performed to investigate this issue.

Published
2019
Full Text
View/download PDF

40. Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study.

Author

Willekens, Rein, Puig-Asensio, Mireia, Ruiz-Camps, Isabel, Larrosa, Maria N, González-López, Juan J, Rodríguez-Pardo, Dolors, Fernández-Hidalgo, Nuria, Pigrau, Carles, and Almirante, Benito

Subjects
ACADEMIC medical centers, ALGORITHMS, BACTEREMIA, BLOODBORNE infections, TUBERCULOSIS of the bones, GENERIC drug substitution, LENGTH of stay in hospitals, HOSPITAL admission & discharge, INTRAVENOUS therapy, JOINT tuberculosis, LONGITUDINAL method, ORAL drug administration, SKIN diseases, STAPHYLOCOCCAL diseases, TREATMENT effectiveness, CATHETER-related infections, DISEASE risk factors, LINEZOLID, THERAPEUTICS
Abstract

Background Oral switch to linezolid is a promising alternative to standard parenteral therapy (SPT) in Staphylococcus aureus bacteremia (SAB). Methods We conducted a prospective cohort study of all adult cases of SAB between 2013 and 2017 in a Spanish university hospital. We compared the efficacy, safety, and length of hospital stay of patients receiving SPT and those where SPT was switched to oral linezolid between days 3 and 9 of treatment until completion. We excluded complicated SAB and osteoarticular infections. A k-nearest neighbor algorithm was used for propensity score matching with a 2:1 ratio. Results After propensity score matching, we included 45 patients from the linezolid group and 90 patients from the SPT group. Leading SAB sources were catheter related (49.6%), unknown origin (20.0%), and skin and soft tissue (17.0%). We observed no difference in 90-day relapse between the linezolid group and the SPT group (2.2% vs 4.4% respectively; P =.87). No statistically significant difference was observed in 30-day all-cause mortality between the linezolid group and the SPT group (2.2% vs 13.3%; P =.08). The median length of hospital stay after onset was 8 days in the linezolid group and 19 days in the SPT group (P <.01). No drug-related events leading to discontinuation were noted in the linezolid group. Conclusions Treatment of SAB in selected low-risk patients with an oral switch to linezolid between days 3 and 9 of treatment until completion yielded similar clinical outcomes as SPT, allowing earlier discharge from the hospital. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

41. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial

Author

Lora-Tamayo, Jaime, primary, Euba, Gorane, additional, Cobo, Javier, additional, Horcajada, Juan Pablo, additional, Soriano, Alex, additional, Sandoval, Enrique, additional, Pigrau, Carles, additional, Benito, Natividad, additional, Falgueras, Luis, additional, Palomino, Julián, additional, del Toro, María Dolores, additional, Jover-Sáenz, Alfredo, additional, Iribarren, José Antonio, additional, Sánchez-Somolinos, Mar, additional, Ramos, Antonio, additional, Fernández-Sampedro, Marta, additional, Riera, Melchor, additional, Baraia-Etxaburu, Josu Mirena, additional, Ariza, Javier, additional, Murillo, Oscar, additional, Ribera, Alba, additional, Cabo, Xavier, additional, Fresco, Gema, additional, Ruiz-Garbajosa, Patricia, additional, Leal, Joan, additional, Puig, Luis, additional, Sorlí, Luisa, additional, Morata, Laura, additional, Bori, Guillem, additional, Martínez-Pastor, Juan C., additional, Rodríguez-Pardo, Dolors, additional, Puig-Asensio, Mireia, additional, Sordé-Masip, Roger, additional, Prats-Gispert, Laura, additional, Pérez-Villar, Ferran, additional, García-Gónzalez, Mercé, additional, Esteban, Jaime, additional, Blanco, Antonio, additional, García-Cañete, Joaquín, additional, Puente, Andrés, additional, Domecq, Gabriel, additional, Álvarez, Rocío, additional, Peñas-Espinar, Cecilia, additional, Muniain-Ezcurra, Miguel Ángel, additional, Suárez, Ana-Isabel, additional, Coll, Pere, additional, Jordán, Marcos, additional, Mur, Isabel, additional, Ibarguren, Maialen, additional, de la Herrán, Gaspar, additional, Sánchez-Romero, Isabel, additional, Jiménez-Cristóbal, Javier, additional, Múñez-Rubio, Elena, additional, Muntaner, Francisco, additional, Ramírez, Antonio, additional, Fariñas, María Carmen, additional, Campo, Cristina, additional, Fakkas, Michel, additional, López-Azkarreta, Íñigo, additional, Ibarra, Sofía, additional, Cisterna, Ramón, additional, and Granados, Ana, additional

Published
2016
Full Text
View/download PDF

50. Efficacy of Teicoplanin-Gentamicin Given Once a Day on the Basis of Pharmacokinetics in Humans for Treatment of Enterococcal Experimental Endocarditis

Author

López, Pedro, primary, Gavaldà, Joan, additional, Martin, M. Teresa, additional, Almirante, Benito, additional, Gomis, Xavier, additional, Azuaje, Carlos, additional, Borrell, Nuria, additional, Pou, Leonor, additional, Falcó, Vicenç, additional, Pigrau, Carles, additional, and Pahissa, Albert, additional

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results